CompletedPhase 2NCT02575300
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Studying Neuroendocrine carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator
- Jonathan Strosberg, M.D.H. Lee Moffitt Cancer Center and Research Institute
- Intervention
- Ibrutinib(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2019
Study locations (1)
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Collaborators
Pharmacyclics LLC.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02575300 on ClinicalTrials.govOther trials for Neuroendocrine carcinoma of pancreas
Additional recruiting or active studies for the same condition.